SCHEMBL2214428

SCHEMBL2214428

COc1cccc(-c2cccc(-c3cc4ccnn4c(Nc4ccc(NC(=O)c5ccc(CNC(=O)OC(C)(C)C)cc5)cc4)n3)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.46
HDAC1 Q13547 2/20 0.43
MAPT P10636 7/20 0.43
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 5/20 0.43
HPGD P15428 5/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
LMNA P02545 3/20 0.43
HTT P42858 2/20 0.43
PLAU P00749 4/20 0.41
PLG P00747 2/20 0.41
PLAT P00750 2/20 0.41
HDAC6 Q9UBN7 1/20 0.41
THRB P10828 1/20 0.41
SLC2A1 P11166 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 2/20 0.40
RECQL P46063 1/20 0.39
TP53 P04637 1/20 0.39
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2213575 0.95 HDAC1 (0.46) NAMPTHDAC1MAPTALDH1A1KDM4E
SCHEMBL2211305 0.90 NAMPT (0.47) NAMPTHDAC1MAPTHDAC6POLB
SCHEMBL2212049 0.90 NAMPT (0.46) NAMPTHDAC1MAPTALDH1A1SMN1; SMN2
SCHEMBL2215354 0.90 PLAU (0.43) NAMPTHDAC1MAPTALDH1A1KDM4E
SCHEMBL2214567 0.88 HDAC1 (0.53) NAMPTHDAC1MAPTKDM4EHDAC6
SCHEMBL2214976 0.87 MAPT (0.47) NAMPTHDAC1MAPTALDH1A1KDM4E
SCHEMBL2212020 0.86 NAMPT (0.46) NAMPTHDAC1MAPTKDM4EHDAC6
SCHEMBL2213295 0.86 NAMPT (0.49) NAMPTHDAC1MAPTKDM4EHDAC6
SCHEMBL2214847 0.85 NAMPT (0.45) NAMPTHDAC1HDAC6
SCHEMBL2212158 0.85 NAMPT (0.43) NAMPTHDAC1MAPTKDM4EHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 NAMPT 2045/4885HDAC1 1147/4885MAPT 3832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.